Will This Fish Oil Deal Affect Amarin?
Amarin's (NAS: AMRN) new triglyceride-lowering drug Vascepa may or may not be a blockbuster when it hits the market. Vascepa's active ingredients are derived from omega-3 fatty acids found in fish oils, as are the active ingredients in Lovaza. This drug, which is sold by pharma giant GlaxoSmithKline (NYS: GSK) , generated more than $900 million in sales last year and will be Vascepa's biggest competition.
Recently, one of Amarin's suppliers -- German chemical company BASF (NASDAQOTH:BASFY) -- announced its intention to acquire a company called Pronova BioPharma, which actually produces Lovaza for GlaxoSmithKline.
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss this deal and its potential impact on investors.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the Vascepa's success is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Will This Fish Oil Deal Affect Amarin? originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
